Clinical Trial

Mechanisms and Targeted Therapy of Airway Basal Cell Dysfunction in Bronchiolitis Obliterans Syndrome

Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
Study was withdrawn prior to enrollment due to dissolution of collaborative partnership. The protocol may be reactivated in the future under new collaboration.
Summary
This experimental study aims to investigate the pathogenesis of bronchiolitis obliterans syndrome (BOS) and provide a basis for clinical diagnosis and treatment. The core research question is: whether there is a causal relationship between stem cell dysfunction induced by the inflammatory microenvironment and airway injury repair during the pathological process of BOS? Researchers will collect alveolar lavage fluid specimens from participants and healthy individuals to isolate distal small airway stem cells for subsequent scientific research and comparative analysis, thereby revealing the pathological mechanisms of BOS, exploring precise intervention targets, and developing innovative therapeutic strategies to improve patient prognosis, long-term survival rates, and quality of life.
Protocol Amendment History 4 changes
critical Trial status changed: Enrolling by Invitation → Withdrawn 2026-07-30
critical Trial withdrawn: Study was withdrawn prior to enrollment due to dissolution of collaborative partnership. The protocol may be reactivated... 2026-07-30
critical Primary endpoint(s) modified 2026-07-30
notable Enrollment reduced: 5 -> 0 participants 2026-07-30
Trial Details
NCT Number NCT07018804
Lead Sponsor Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Conditions Bronchiolitis Obliterans Syndrome (BOS)
Start Date 2026-07-26
Primary Completion 2027-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-29